<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957709</url>
  </required_header>
  <id_info>
    <org_study_id>2705.00</org_study_id>
    <secondary_id>NCI-2013-01779</secondary_id>
    <secondary_id>2705</secondary_id>
    <secondary_id>2705.00</secondary_id>
    <secondary_id>K12CA076930</secondary_id>
    <secondary_id>K23CA175167</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01957709</nct_id>
  </id_info>
  <brief_title>Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma</brief_title>
  <official_title>A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Horizon Pharma USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in
      treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of
      tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether systemic administration of interferon (IFN) gamma (recombinant
      interferon gamma) will increase class I major histocompatibility complex (MHC) expression in
      synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) tumors.

      SECONDARY OBJECTIVES:

      I. To determine whether systemic administration of IFN gamma will increase class II MHC
      expression in SS and MRCL tumors.

      II. To examine changes in the immune response to MRCL and SS by examining changes in the
      immune infiltrates, antibody response and antigen specific T cell response before and after
      IFN gamma treatment.

      OUTLINE:

      Patients receive recombinant interferon gamma subcutaneously (SC) every 7 days for 4 weeks
      before surgery.

      After completion of study, patients are followed up at 2 weeks post-surgery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enough samples were collected for data analysis.
  </why_stopped>
  <start_date type="Actual">September 25, 2013</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>100 mcg/m2 weekly injection for four weeks</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Class I Major Histocompatibility Complex (MHC) Expression After Treatment With IFN Gamma</measure>
    <time_frame>Baseline to up to 2 weeks post-surgery</time_frame>
    <description>It would be highly relevant to observe marked increase macrophages (effect size &gt; 2.5). Four patients gives over 90% power to detect such a large increase with a two-tailed alpha of 0.05.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MHC Class II Expression</measure>
    <time_frame>Baseline to 2 weeks post biopsy.</time_frame>
    <description>To determine whether systemic administration of IFNg will increase class II MHC expression in SS and MRCL tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Immune Response</measure>
    <time_frame>Baseline to 2 weeks post biopsy</time_frame>
    <description>To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFNg treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Myxoid Liposarcoma</condition>
  <condition>Round Cell Liposarcoma</condition>
  <condition>Synovial Sarcoma</condition>
  <arm_group>
    <arm_group_label>Basic science (interferon gamma and MHC expression)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Basic science (interferon gamma and MHC expression)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Gamma</intervention_name>
    <description>Given subcutaneously weekly for four weeks prior to surgery.</description>
    <arm_group_label>Basic science (interferon gamma and MHC expression)</arm_group_label>
    <other_name>Gamma Interferon (GEN)</other_name>
    <other_name>Gamma Interferon-SCH</other_name>
    <other_name>Gamma-Interferon</other_name>
    <other_name>Ginterferon</other_name>
    <other_name>IFN-g</other_name>
    <other_name>Interferon Gamma</other_name>
    <other_name>Interferon Gamma (BIO)</other_name>
    <other_name>Interferon, Gamma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of synovial sarcoma and myxoid/round cell liposarcoma

          2. Male or female subject, 18 or older

          3. A superficial tumor easily and safely accessible for a research biopsy or are being
             considered for resection or biopsy of their tumor as part of standard of care and have
             recent pathology.

          4. Zubrod performance status of '0-2' or Karnofsky score &gt; 60%

          5. No treatment with systemic anti-cancer treatment (chemotherapy or biologics) within 2
             weeks of starting interferon gamma

          6. Patients with a history of coronary artery disease must have had a normal stress test
             within 180 days of starting IFN gamma

          7. Must have been off metformin for at least 2 weeks prior to starting IFN gamma

          8. No use of full dose, therapeutic anti-coagulation. However, low dose warfarin for
             catheter prophylaxis or acetylsalicylic acid are acceptable.

          9. No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of
             starting IFN gamma

        Exclusion Criteria:

          1. Active infection requiring oral or intravenous antibiotics

          2. Pregnant women, nursing mothers, men or women of reproductive ability who are
             unwilling to use effective contraception or abstinence. Women of childbearing
             potential must have a negative pregnancy test within two weeks prior to entry.

          3. Serum creatinine &gt; 1.5 mg/dL or Glomerular Filtration Rate &lt; 50

          4. Significant hepatic dysfunction (SGOT &gt; 150 IU or &gt; 3x upper limit of normal;
             bilirubin &gt; 1.6 mg/dL; prothrombin time &gt; 1.5x control).

          5. Known central nervous system (CNS) metastasis. Once CNS metastasis have been treated
             these patients may participate if they are otherwise good trial candidates.

          6. Current treatment with steroids (must be discontinued 1 week before starting IFN
             gamma)

          7. Hemoglobin A1C &gt; 8.5%

          8. Uncontrolled hypertension, blood pressure (BP) &gt; 150/100 mmHg; patients with elevated
             BP may enroll once BP is corrected

          9. Cancer/testis antigen 1B (NY-ESO-1) specific T cell therapy within 1 year of starting
             on the trial

         10. New (&lt; 6 months) cardiac arrhythmia (electrocardiogram [EKG] should be performed
             within 2 weeks of starting IFN gamma).

         11. History of clinically significant congestive heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth Pollack</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <results_first_submitted>May 28, 2019</results_first_submitted>
  <results_first_submitted_qc>June 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2019</results_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01957709/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was done in the Seattle Cancer Care Alliance medical clinic, or by patient referral.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Basic Science (Interferon Gamma and MHC Expression)</title>
          <description>Patients receive recombinant interferon gamma SC weekly for 4 weeks before surgery.
Laboratory Biomarker Analysis: Correlative studies
Recombinant Interferon Gamma: Given Subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient refused to complete post-tx bx</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Basic Science (Interferon Gamma and MHC Expression)</title>
          <description>Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.
Laboratory Biomarker Analysis: Correlative studies
Recombinant Interferon Gamma: Given SC</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Class I Major Histocompatibility Complex (MHC) Expression After Treatment With IFN Gamma</title>
        <description>It would be highly relevant to observe marked increase macrophages (effect size &gt; 2.5). Four patients gives over 90% power to detect such a large increase with a two-tailed alpha of 0.05.</description>
        <time_frame>Baseline to up to 2 weeks post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basic Science (Interferon Gamma and MHC Expression)</title>
            <description>Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.
Laboratory Biomarker Analysis: Correlative studies
Recombinant Interferon Gamma: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Class I Major Histocompatibility Complex (MHC) Expression After Treatment With IFN Gamma</title>
          <description>It would be highly relevant to observe marked increase macrophages (effect size &gt; 2.5). Four patients gives over 90% power to detect such a large increase with a two-tailed alpha of 0.05.</description>
          <units>percentage of MHC Class I+ on tumor cell</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.91" lower_limit=".131" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="1.39" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MHC Class II Expression</title>
        <description>To determine whether systemic administration of IFNg will increase class II MHC expression in SS and MRCL tumors.</description>
        <time_frame>Baseline to 2 weeks post biopsy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basic Science (Interferon Gamma and MHC Expression)</title>
            <description>Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.
Laboratory Biomarker Analysis: Correlative studies
Recombinant Interferon Gamma: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>MHC Class II Expression</title>
          <description>To determine whether systemic administration of IFNg will increase class II MHC expression in SS and MRCL tumors.</description>
          <units>percentage of MHC Class II on tumor cell</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.556" lower_limit="0.0" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.125" lower_limit="0.0" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Immune Response</title>
        <description>To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFNg treatment.</description>
        <time_frame>Baseline to 2 weeks post biopsy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basic Science (Interferon Gamma and MHC Expression)</title>
            <description>Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.
Laboratory Biomarker Analysis: Correlative studies
Recombinant Interferon Gamma: Given SC</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Immune Response</title>
          <description>To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFNg treatment.</description>
          <units>percentage of T cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.015" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.074" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients will be evaluated at their baseline visit prior to administration of the IFNg through two weeks following their surgery. Ideally this will be a period of 6-10 weeks, depending on the number of times a patient received IFNg subcutaneously and when their surgery was scheduled.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Basic Science (Interferon Gamma and MHC Expression)</title>
          <description>Patients receive recombinant interferon gamma SC every 7 days for 4 weeks before surgery or thrice weekly for 2 weeks before surgery.
Laboratory Biomarker Analysis: Correlative studies
Recombinant Interferon Gamma: Given SC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <description>Grade 1: all events</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1: 4 events Grade 2: 1 event</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Grade 1: all events</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 1: all events</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>Grade 1: all events</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Biopsy site pain</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Body Aches</sub_title>
                <description>Grade 1: all events</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Grade 1: all events</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of trial due to collection of enough data necessary to complete analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Seth Pollack, MD</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-6629</phone>
      <email>spollack@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

